

To: [REDACTED]@LIST.NIH.GOV [REDACTED]@LIST.NIH.GOV]
From: International Cancer Screening Network
Sent: Thur 12/17/2020 7:32:21 AM
Subject: Update on the ICSN survey and the COVID-19 and Cancer Global Modelling Consortium
Received: Thur 12/17/2020 2:58:58 PM
[ICSN COVID-19 Survey - Dec 15 2020.pdf](#)
[Lansdorp CCGMC for ICSN members.pdf](#)

Dear Colleagues,

We hope this message finds you well and safe at the end of a year that was centered around the COVID-19 emergency. Our deepest sympathy goes to all that have lost relatives or friends or that have been affected in any other way by this pandemic.

In the midst of this emergency, many of you took the time out of your busy schedules to contribute to the ICSN survey about the impact of COVID-19 on cancer screening worldwide. We appreciate the time you have dedicated to answering our questions, considering that many of you have increased tasks and responsibilities given the COVID-19 emergency.

While we are still working on the analysis of the survey data, we wanted to give you an update and share some preliminary results with you. In short:

- The ICSN leadership has been working on a literature review on previous disruptions to screening services, which will be submitted for publication shortly. The review has highlighted the main themes of coordination, communication, resources and patient follow-up as key elements in the response to the current but also potential future pandemics.
- These same themes will be applied to the survey results to organize the data and the comments you have submitted in response to our questions. Details on the survey uptake and some preliminary results are summarized in the presentation attached to this message.
- The survey results will be published as part of a special issue of [REDACTED] and [REDACTED], focusing on the COVID impact on cancer screening. This special issue is to be published in the summer of 2021.
- Before the publication, a webinar is being planned for early 2021 to provide ICSN members with an update of the survey results.

Also attached is a presentation with an overview of the UICC COVID-19 and Cancer Taskforce Global Modelling Consortium and preliminary results from their main projects [REDACTED] on behalf of ICSN, is leading the activities related to cancer screening and more information can be found on <https://ccgmc.org/>. Further results will be presented at the ICSN webinar early 2021.

For now, I wish you a well-deserved Holiday Season and all the best for the New Year.

On behalf of the ICSN Steering Committee,
 Warm regards,

[REDACTED]

[REDACTED]

 [REDACTED]

LRCB | Dutch Expert Centre for Screening
 PO Box 6873 | 6503 GJ Nijmegen | tel: 00-31-(0) [REDACTED] | [REDACTED]@lrcb.nl

Radboudumc | Department for Health Evidence
 PO Box 9101 | 6500 HB Nijmegen | tel: 00-31-(0) [REDACTED] | [REDACTED]@radboudumc.nl

De informatie in dit bericht is uitsluitend bestemd voor de geadresseerde. Aan dit bericht en de bijlagen kunnen geen rechten worden ontleend. Heeft u deze e-mail onbedoeld ontvangen? Dan verzoeken wij u het te vernietigen en de afzender te informeren. Openbaar maken, kopiëren en verspreiden van deze e-mail of informatie uit deze e-mail is alleen toegestaan met voorafgaande schriftelijke toestemming van de afzender. Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 41055629.

The content of this message is intended solely for the addressee. No rights can be derived from this message or its attachments. If you are not the intended recipient, we kindly request you to delete the message and inform the sender. It is strictly prohibited to disclose, copy or

distribute this email or the information inside it, without a written consent from the sender. Radboud university medical center is registered with the Dutch Chamber of Commerce trade register with number 41055629.

To unsubscribe from the ICSNLIST list, click the following link:

<http://list.nih.gov/cgi-bin/wa.exe?SUBED1=ICSNLIST&A=1>